Cover - shares

Document Information [Line Items]

Document Type
Amendment Flag
Document Period End Date
Document Fiscal Year Focus
Document Fiscal Period Focus
Document Quarterly Report
Document Transition Report
Entity File Number
Entity Registrant Name
Entity Central Index Key
Current Fiscal Year End Date
Entity Incorporation, State or Country Code
Entity Tax Identification Number
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Postal Zip Code
City Area Code
Local Phone Number
Title of 12(b) Security
Trading Symbol
Security Exchange Name
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Entity Ex Transition Period
Entity Shell Company
Common Class A [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding
Common Class B [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding
 6 Months Ended
Jun. 30, 2024 Aug. 06, 2024

10-Q
false
Jun. 30, 2024
2024
Q2
true
false
001-42130
Tempus AI, Inc.
0001717115
--12-31
DE
47-4903308
600 West Chicago Avenue
Suite 510
Chicago
IL
60654
800
976-5448
Class A common stock, $0.0001 par value per share
TEM
NASDAQ
No
Yes
Non-accelerated Filer
false
true
false
false

149,274,923

5,043,789
 Condensed Consolidated Balance Sheets - USD ($) $ in Thousands
Current Assets
Cash and cash equivalents
Accounts receivable, net of allowances of $1,092 and $1,115 at June 30, 2024 and December
31, 2023, respectively
Inventory
Warrant asset
Prepaid expenses and other current assets
Marketable equity securities
Deferred offering costs
Total current assets
Property and equipment, net
Goodwill
Warrant asset, less current portion
Intangible assets, net
Investments and other assets
Warrant contract asset, less current portion
Operating lease right-of-use assets
Restricted cash
Total Assets
Current Liabilities
Accounts payable
Accrued expenses
Deferred revenue
Other current liabilities
Operating lease liabilities
Accrued data licensing fees
Accrued dividends
Total current liabilities
Operating lease liabilities, less current portion
Convertible promissory note
Warrant liability
Other long-term liabilities
Interest payable
Long-term debt, net
Deferred revenue, less current portion
Total Liabilities
Commitments and contingencies
Convertible redeemable preferred stock, $0.0001 par value, no and 69,803,765 shares
authorized at June
Stockholders' 30, 2024
equity and December 31, 2023, respectively; no and 63,525,953 shares
(deficit)
Treasury Stock, 145,466 shares at June 30, 2024 and December 31, 2023, at cost
Additional Paid-In Capital
Accumulated Other Comprehensive (Loss) Income
Accumulated deficit
Total Stockholders' equity (deficit)
Total Liabilities, Convertible redeemable preferred stock, and Stockholders' equity (deficit)
Common Class A [Member]
Stockholders' equity (deficit)
Common stock value issued
Common Class B [Member]
Stockholders' equity (deficit)
Common stock value issued
Nonvoting Common Stock [Member]
Stockholders' equity (deficit)
Common stock value issued
Jun. 30, 2024 Dec. 31, 2023

$ 478,811 $ 165,767
118,106 94,462
32,690 28,845
800 5,070
29,704 17,295
11,255 31,807
0 7,085
671,366 350,331
60,539 61,681
73,345 73,354
1,500 4,930
16,252 21,916
7,677 8,971
19,077 21,499
13,994 20,530
861 840
864,611 564,052

28,646 54,421
85,185 82,517
50,905 64,860
7,273 8,213
5,828 6,437
3,727 6,382
0 9,797
181,564 232,627
27,238 32,040
180,648 193,124
33,600 34,500
16,790 19,751
62,608 55,321
261,853 256,541
2,059 16,768
766,360 840,672

0 1,105,543

(3,602) (3,602)
2,163,911 18,345
(94) 5
(2,061,980) (1,396,917)
 98,251 (1,382,163)
864,611 564,052

15 6

1 0

$0 $0
 Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands
Accounts receivable, net of allowances
Temporary equity shares authorized
Temporary equity shares outstanding
Temporary equity liquidation preference
Treasury stock common shares
Redeemable Convertible Preferred Stock [Member]
Temporary equity par or stated value per share
Temporary equity shares authorized
Temporary equity shares issued
Temporary equity shares outstanding
Temporary equity liquidation preference
Common Class A [Member]
Common stock par or stated value per share
Common stock shares authorized
Common stock shares issued
Common stock shares outstanding
Common Class B [Member]
Common stock par or stated value per share
Common stock shares authorized
Common stock shares issued
Common stock shares outstanding
Nonvoting Common Stock [Member]
Common stock par or stated value per share
Common stock shares authorized
Common stock shares issued
Common stock shares outstanding
Jun. 30, 2024 Dec. 31, 2023
$ 1,092 $ 1,115
69,803,765
63,525,953
$ 1,130,429
145,466 145,466

$ 0.0001 $ 0.0001
0 69,803,765
0 63,525,953
0 63,525,953
$0 $ 1,130,429

$ 0.0001 $ 0.0001
1,000,000,000 200,228,024
149,274,923 58,367,961
149,274,923 58,367,961

$ 0.0001 $ 0.0001
5,500,000 5,374,899
5,043,789 0
5,043,789 0

$ 0.0001 $ 0.0001
0 66,946,627
0 5,205,802
0 5,060,336
 Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $
in Thousands
Net revenue
Total net revenue
Cost and operating expenses
Technology research and development
Research and development
Selling, general and administrative
Total cost and operating expenses
Loss from operations
Interest income
Interest expense
Other (expense) income, net
Loss before provision for income taxes
Provision for income taxes
Losses from equity method investments
Net Loss
Dividends on Series A, B, B-1, B-2, C, D, E, F, G, G-3, and G-4 preferred shares
Cumulative Undeclared Dividends on Series C preferred shares
Net loss attributable to common shareholders, basic
Net loss attributable to common shareholders, diluted
Net loss per share attributable to common shareholders, basic
Net loss per share attributable to common shareholders, diluted
Weighted-average shares outstanding used to compute net loss per share, basic
Weighted-average shares outstanding used to compute net loss per share, diluted
Comprehensive Loss, net of tax
Net loss
Foreign currency translation adjustment
Comprehensive loss
Genomics [Member]
Net revenue
Total net revenue
Cost and operating expenses
Cost of revenues
Data and services [Member]
Net revenue
Total net revenue
Cost and operating expenses
Cost of revenues
 3 Months Ended 6 Months Ended
Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023

$ 165,969 $ 132,417 $ 311,789 $ 248,041

77,908 23,427 104,975 46,329

68,025 22,171 92,365 43,034
463,072 71,189 542,636 140,236
699,461 177,555 898,555 347,040
(533,492) (45,138) (586,766) (98,999)
1,718 1,957 2,749 4,381
(13,295) (11,712) (26,533) (20,903)
(7,048) (766) (6,299) 5,622
(552,117) (55,659) (616,849) (109,899)
(95) (3) (106) (9)
0 (170) 0 (301)
(552,212) (55,832) (616,955) (110,209)
(11,540) (10,897) (39,347) (21,566)
(668) (745) (1,174) (1,466)
(564,420) (67,474) (657,476) (133,241)
$ (564,420) $ (67,474) $ (657,476) $ (133,241)
$ (6.86) $ (1.07) $ (9.02) $ (2.11)
$ (6.86) $ (1.07) $ (9.02) $ (2.11)
82,325 63,286 72,930 63,257
82,325 63,286 72,930 63,257

$ (552,212) $ (55,832) $ (616,955) $ (110,209)

(43) 53 (99) 25
(552,255) (55,779) (617,054) (110,184)

112,324 91,924 214,893 173,982

68,324 46,961 121,159 92,241

53,645 40,493 96,896 74,059

$ 22,132 $ 13,807 $ 37,420 $ 25,200

 Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands

Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities
Change in fair value of warrant liability
Stock-based compensation
Gain on warrant exercise
Gain on marketable equity securities
Amortization of original issue discount
Amortization of deferred financing fees
Change in fair value of contingent consideration
Amortization of warrant contract asset
Depreciation and amortization
Provision for bad debt expense
Change in fair value of warrant asset
Loss from equity-method investments
Amortization of finance right-of-use lease assets
Non-cash operating lease costs
Minimum accretion expense
Impairment of intangible assets
PIK interest added to principal
Change in assets and liabilities
Accounts receivable
Inventory
Prepaid expenses and other current assets
Investments and other assets
Accounts payable
Deferred revenue
Accrued data licensing fees
Accrued expenses & other
Interest payable
Operating lease liabilities
Net cash used in operating activities
Investing activities
Purchases of property and equipment
Proceeds from sale of marketable equity securities
Business combinations, net of cash acquired
Net cash provided by (used in) investing activities
Financing activities
Proceeds from issuance of common stock in connection with initial public offering, net of
underwriting discounts
Tax withholding relatedand commissions
to net share settlement of restricted stock units
Issuance of Series G-5 Preferred Stock
Principal payments on finance lease liabilities
Purchase of treasury stock
Payment of deferred offering costs
Dividends paid
Proceeds from long-term debt, net of original issue discount
Payment of indemnity holdback related to acquisition
Net cash provided by financing activities
Effect of foreign exchange rates on cash
Net increase (decrease) in Cash, Cash Equivalents and Restricted Cash
Cash, cash equivalents and restricted cash, beginning of period
Cash, cash equivalents and restricted cash, end of period
Cash, Cash Equivalents and Restricted Cash are Comprised of:
Cash and cash equivalents
Restricted cash and cash equivalents
Total cash, cash equivalents and restricted cash
Supplemental disclosure of cash flow information
Cash paid during the year for interest
Cash paid for income taxes
Supplemental disclosure of noncash investing and financing activities
Dividends Payable
Purchases of property and equipment, accrued but not paid
Deferred offering costs, accrued but not yet paid
Redemption of convertible promissory note
Non-voting common stock issued in connection with business combinations
Operating lease liabilities arising from obtaining right-of-use assets
Conversion of redeemable convertible preferred stock to common stock in connection with
initial public offering
Reclassificiation of deferred offering costs to additional paid-in capital upon initial public
offering
Taxes related to net share settlement of restricted stock units not yet paid
Series G Three Redeemable Convertible Preferred Stock [Member]
Supplemental disclosure of noncash investing and financing activities
Issuance of Series
Series G Four Redeemable Convertible Preferred Stock [Member]
Supplemental disclosure of noncash investing and financing activities
Issuance of Series
 6 Months Ended
Jun. 30, 2024 Jun. 30, 2023

$ (616,955) $ (110,209)

(900) (5,700)
488,313 0
(173) 0
(2,541) 0
691 489
255 255
165 0
2,422 3,307
18,348 16,185
327 1,376
7,700 0
0 301
0 190
3,252 3,382
92 187
0 7,359
4,366 297

(23,971) (6,850)
(3,845) (5,101)
(12,409) (1,634)
1,294 (4,528)
(33,371) (4,195)
(28,669) (19,974)
(2,749) (7,608)
(2,805) 8,125
7,287 7,611
(4,582) (4,352)
(198,458) (121,087)

(14,116) (15,906)
23,098 0
0 (2,869)
8,982 (18,775)

381,951 0
(69,918) 0
199,750 0
 0 (192)
0 (3,602)
(2,714) (151)
(5,625) (5,625)
0 48,750
(813) 0
502,631 39,180
(90) 28
313,065 (100,654)
166,607 303,731
479,672 203,077

478,811 202,266
861 811
479,672 203,077

13,921 5,691
89 41

5,487 4,545
1,108 2,952
6,051 2,917
12,476 13,926
344 4,305
0 892
1,348,809 0
12,347 0
164 0

3,809 2,738

$ 611 $0
 Condensed Consolidated Statements of Redeemable Convertible Preferred Stock,
Common Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands
Beginning Balance, Shares at Dec. 31, 2022
Beginning Balance at Dec. 31, 2022
Beginning Balance, Shares at Dec. 31, 2022
Beginning Balance at Dec. 31, 2022
Issuance of Series Preferred Stock
Issuance of Series Preferred Stock, Shares
Foreign currency translation adjustment
Repurchase of Non-voting Common Stock
Repurchase of Non-voting Common Stock, Shares
Common stock issued in connection with business combination
Common stock issued in connection with business combination, Shares
Dividends
Dividends
Net loss
Ending Balance at Jun. 30, 2023
Ending Balance, Shares at Jun. 30, 2023
Ending Balance at Jun. 30, 2023
Ending Balance, Shares at Jun. 30, 2023
Beginning Balance, Shares at Mar. 31, 2023
Beginning Balance at Mar. 31, 2023
Beginning Balance, Shares at Mar. 31, 2023
Beginning Balance at Mar. 31, 2023
Foreign currency translation adjustment
Dividends
Dividends
Net loss
Ending Balance at Jun. 30, 2023
Ending Balance, Shares at Jun. 30, 2023
Ending Balance at Jun. 30, 2023
Ending Balance, Shares at Jun. 30, 2023
Beginning Balance, Shares at Dec. 31, 2023
Beginning Balance at Dec. 31, 2023
Beginning Balance, Shares at Dec. 31, 2023
Beginning Balance at Dec. 31, 2023
Issuance of Series Preferred Stock
Issuance of Series Preferred Stock, Shares
Foreign currency translation adjustment
Common stock issued in connection with business combination
Common stock issued in connection with business combination, Shares
Issuance of common stock upon settlement of restricted stock units, net
Issuance of common stock upon settlement of restricted stock units, net (Shares)
Issuance of common stock
Issuance of common stock (Shares)
Conversion of redeemable convertible preferred stock to common stock in connection with
initial publicofoffering
Conversion (Shares)
redeemable convertible preferred stock to common stock in connection with
initial public offering
Conversion of redeemable convertible preferred stock to common stock in connection with
initial publicofoffering
Conversion redeemable convertible preferred stock to common stock in connection with
initial publicofoffering
Conversion (Shares)
non-voting common stock to Class A common stock
Conversion of non-voting common stock to Class A common stock (Shares)
Stock-based compensation expense
Dividends
Dividends
Net loss
Ending Balance at Jun. 30, 2024
Ending Balance, Shares at Jun. 30, 2024
Ending Balance at Jun. 30, 2024
Ending Balance, Shares at Jun. 30, 2024
Beginning Balance, Shares at Mar. 31, 2024
Beginning Balance at Mar. 31, 2024
Beginning Balance, Shares at Mar. 31, 2024
Beginning Balance at Mar. 31, 2024
Issuance of Series Preferred Stock
Issuance of Series Preferred Stock, Shares
Foreign currency translation adjustment
Issuance of common stock upon settlement of restricted stock units, net
Issuance of common stock upon settlement of restricted stock units, net (Shares)
Issuance of common stock
Issuance of common stock (Shares)
Conversion of redeemable convertible preferred stock to common stock in connection with
initial publicofoffering
Conversion (Shares)
redeemable convertible preferred stock to common stock in connection with
initial publicofoffering
Conversion redeemable convertible preferred stock to common stock in connection with
initial publicofoffering
Conversion redeemable convertible preferred stock to common stock in connection with
initial public offering
Conversion of non-voting (Shares)
common stock to Class A common stock
Conversion of non-voting common stock to Class A common stock (Shares)
Stock-based compensation expense
Dividends
Dividends
Net loss
Ending Balance at Jun. 30, 2024
Ending Balance, Shares at Jun. 30, 2024
Ending Balance at Jun. 30, 2024
Ending Balance, Shares at Jun. 30, 2024
 Total IPO [Member] Excercise Of Warrants [Member] Treasury Stock [Member]

0
$ (1,129,027)

25
(3,602) $ (3,602)
(145,466)
4,305

(21,566)
(110,209)
(1,260,074) $ (3,602)
(145,466)

(145,466)
(1,193,398) $ (3,602)
53

(10,897)
(55,832)
$ (1,260,074) $ (3,602)
(145,466)

63,525,953

(145,466)
$ (1,382,163) $ (3,602)

(99)
344

(70,082)

$ 369,604 $ (173)
 1,348,809

488,313

(39,347)
(616,955)
98,251 $ (3,602)
(145,466)

(145,466)
(1,474,425) $ (3,602)

(43)
(70,082)

$ 369,604 $ (173)

1,348,809

488,313

(11,540)
(552,212)
$ 98,251 $ (3,602)
(145,466)
Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] IPO [Member]

$ 9,251

4,305

13,556

13,556

13,556

18,345

344

(70,082)

$ 369,603
 1,357,562

(1)

488,313

2,163,911

18,689

(70,082)

$ 369,603

1,357,562

(1)

488,313

$ 2,163,911
Additional Paid-in Capital [Member] Excercise Of Warrants [Member]

$ (173)
$ (173)
Accumulated Deficit [Member] Accumulated Other Comprehensive (Loss) Income [Member]

$ (1,138,302) $ 18

25

(21,566)
(110,209)
(1,270,077) 43

(1,203,348) (10)
53

(10,897)
(55,832)
(1,270,077) 43

(1,396,917) 5

(99)
 (8,761)

(39,347)
(616,955)
(2,061,980) (94)

(1,489,467) (51)

(43)

(8,761)

(11,540)
(552,212)
$ (2,061,980) $ (94)
Redeemable Convertible Preferred Stock [Member]

63,525,953
0

0
Redeemable Convertible Preferred Stock [Member] Common Stock [Member]
62,692,927
$ 1,026,143

13,980

$ 1,042,861
62,740,708
62,740,708
$ 1,034,321

8,540

$ 1,042,861
62,740,708
63,525,953
$ 1,105,543
(67,093,065)
$ (1,343,382)

33,669

$0
0
63,603,084
$ 1,134,802

(67,093,065)
$ (1,343,382)

8,830

$0
0
Redeemable Convertible Preferred Stock [Member] Common Stock [Member] Series G-3
Preferred Stock [Member]

$ 2,738
47,781

$ 3,809
66,465
Redeemable Convertible Preferred Stock [Member] Common Stock [Member] Series G-5
Preferred Stock [Member]

$ 199,750
3,489,981
$ 199,750
3,489,981
Redeemable Convertible Preferred Stock [Member] Common Stock [Member] Series G-4
Preferred Stock [Member]

$ 611
10,666
Class A Voting Stock [Member] Class A Voting Stock [Member] Common Stock [Member]

58,367,961
$6

$6
58,367,961

58,367,961
$6

$6
58,367,961

58,367,961
$6

$0
2,651,848
 $7
71,976,178
$1
5,069,477

$ 15
149,274,923

58,367,961
$6

$0
2,651,848

71,976,178

$7
71,976,178
$1
5,069,477

$ 15
149,274,923
Class A Voting Stock [Member] Common Stock [Member] IPO [Member]

$1
11,100,000

$1
11,100,000
Class A Voting Stock [Member] Common Stock [Member] Excercise Of Warrants [Member]

$0
109,459

$0
109,459
Class B Voting Stock [Member] Common Stock [Member]

$0
0

0
$0

$0
0
 $1
5,043,789

$1
5,043,789

0
$0

$1
5,043,789

$1
5,043,789
Class B Voting Stock [Member] Common Stock [Member] Excercise Of Warrants [Member]

$0
Non-voting Common Stock [Member] Common Stock [Member]

4,932,415
$0

$0
130,874

$0
5,063,289

5,063,289
$0

$0
5,063,289

5,205,802
$0

$0
9,141
 $0
(5,214,943)

$0
0

5,214,943
$0

$0
(5,214,943)

$0
0
 3 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands
Jun. 30, 2024 Jun. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss) $ (552,212) $ (55,832)
 6 Months Ended
Jun. 30, 2024 Jun. 30, 2023

$ (616,955) $ (110,209)
 Insider Trading Arrangements

Eric Lefkofsky [Member]

Trading Arrangements, by Individual
Name
Title
Rule 10b5-1 Arrangement Adopted
Adoption Date
Rule 10b5-1 Arrangement Terminated
Termination Date
Aggregate Available
Ryan Fukushima [Member]
Trading Arrangements, by Individual
Name
Title
Rule 10b5-1 Arrangement Adopted
Adoption Date
Rule 10b5-1 Arrangement Terminated
Termination Date
Aggregate Available
Erik Phelps [Member]
Trading Arrangements, by Individual
Name
Title
Rule 10b5-1 Arrangement Adopted
Adoption Date
Rule 10b5-1 Arrangement Terminated
Termination Date
Aggregate Available
Andrew Polovin [Member]
Trading Arrangements, by Individual
Name
Title
Rule 10b5-1 Arrangement Adopted
Adoption Date
Rule 10b5-1 Arrangement Terminated
Termination Date
Aggregate Available
James Rogers [Member]
Trading Arrangements, by Individual
Name
Title
Rule 10b5-1 Arrangement Adopted
Adoption Date
Rule 10b5-1 Arrangement Terminated
Termination Date
Aggregate Available
Ryan Bartolucci [Member]
Trading Arrangements, by Individual
Name
Title
Rule 10b5-1 Arrangement Adopted
Adoption Date
Rule 10b5-1 Arrangement Terminated
Termination Date
Aggregate Available

[1]Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under t
[2]Represents the adoption of a Rule 10b5-1 trading plan by each of Blue Media, LLC and Gray Media, LLC, each an entit
 6 Months Ended
Jun. 30, 2024 shares

Eric Lefkofsky
Chief Executive Officer
true
June 14, 2024
true [1],[2]
June 18, 2025
2,000,000 [2]

Ryan Fukushima
Chief Operating Officer
true
June 14, 2024
true [1],[2]
June 30, 2025
240,000

Erik Phelps
Executive Vice President
true
June 14, 2024
true [1],[2]
June 30, 2025
0 [3]

Andrew Polovin
Executive Vice President
true
June 14, 2024
true [1],[2]
June 30, 2025
0 [4]

James Rogers
Chief Financial Officer
true
 June 14, 2024
true [1],[2]
June 15, 2025
0 [4]

Ryan Bartolucci
Chief Accounting Officer
true
June 14, 2024
true [1],[2]
June 30, 2025
0 [4]

conditions of Rule 10b5-1(c) under the Exchange Act.

C and Gray Media, LLC, each an entity controlled by Mr.
 Description of Business

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Description of Business
 6 Months Ended
Jun. 30, 2024

1. DESCRIPTION OF BUSINESS Company Information Tempus AI, Inc., together with the
subsidiaries through which it conducts business (the “Company”), is a healthcare technology
 Summary of Significant Accounting Policies

Accounting Policies [Abstract]

Summary of Significant Accounting Policies
 6 Months Ended
Jun. 30, 2024

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation and Basis

of Presentation The condensed consolidated financial statements include the accounts of
 Revenue Recognition

Revenue Recognition [Abstract]

Revenue Recognition
 6 Months Ended
Jun. 30, 2024

3. REVENUE RECOGNITION The Company derives revenue from selling lab services
(“Genomics”) to physicians, academic research institutions, and other parties. The Company
 Business Combinations

Business Combinations [Abstract]

Business Combinations
 6 Months Ended
Jun. 30, 2024

4. BUSINESS COMBINATIONS SEngine On October 3, 2023, the Company acquired all of the
issued and outstanding interests of SEngine Precision Medicine LLC (“SEngine”), a Delaware
 Balance Sheet Components

Balance Sheet Related Disclosures [Abstract]

Balance Sheet Components
 6 Months Ended
Jun. 30, 2024

5. BALANCE SHEET COMPONENTS Property and Equipment, net The following summarizes
property and equipment, net as of June 30, 2024 and December 31, 2023 (in thousands):
 Goodwill and Intangibles

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangibles
 6 Months Ended
Jun. 30, 2024

6. GOODWILL AND INTANGIBLES Goodwill Goodwill represents the excess of the purchase
price in a business combination over the fair value of net tangible and intangible assets
 Commitments and Contingencies

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies
 6 Months Ended
Jun. 30, 2024

7. COMMITMENTS AND CONTINGENCIES Legal Matters From time to time in the normal
course of business, the Company may be subject to various legal matters such as threatened
 Stockholders' Equity

Stockholders' Equity Note [Abstract]

Stockholders' Equity
 6 Months Ended
Jun. 30, 2024

8. STOCKHOLDERS’ EQUITY Common Stock Prior to the IPO, the Company had authorized two
classes of common stock, voting and non-voting. In March non-voting G-5 Class A common
Redeemable Convertible Preferred Stock

Temporary Equity Disclosure [Abstract]

Redeemable Convertible Preferred Stock
 6 Months Ended
Jun. 30, 2024

9. REDEEMABLE CONVERTIBLE PREFERRED STOCK In January 2023, the Company issued

47,781 shares of Series G-3 paid-in-kind In January 2024, the Company issued 66,465 shares
 Stock-based compensation

Share-Based Payment Arrangement [Abstract]

Stock-based compensation
 6 Months Ended
Jun. 30, 2024

10. STOCK-BASED COMPENSATION 2015 Stock Plan In 2015, the Company adopted the
Tempus AI, Inc. 2015 Stock Plan (the “2015 Plan”), which has been amended and restated
 Debt

Debt Disclosure [Abstract]

Debt
 6 Months Ended
Jun. 30, 2024

11. DEBT Term Loan Facility On September 22, 2022, the Company entered into a Credit
Agreement with Ares Capital Corporation (“Ares”) for a senior secured loan (the “Term Loan
 Net Loss Per Share Attributable to Common Stockholders

Earnings Per Share [Abstract]

Net Loss Per Share Attributable to Common Stockholders
 6 Months Ended
Jun. 30, 2024

12. NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS Basic net loss per
share is calculated by dividing the net loss by the weighted average number of outstanding
 Income Taxes

Income Tax Disclosure [Abstract]

Income Taxes
 6 Months Ended
Jun. 30, 2024

13. INCOME TAXES Accounting for income taxes for interim periods generally requires the
provision for income taxes to be determined by applying an estimate of the annual effective
 Fair Value Measurements

Fair Value Disclosures [Abstract]

Fair Value Measurements
 6 Months Ended
Jun. 30, 2024

14. FAIR VALUE MEASUREMENTS The carrying amounts of financial instruments, including
cash and cash equivalents, accounts receivable, finance lease obligations, minimum royalties,
 Related Parties

Related Party Transactions [Abstract]

Related Parties
 6 Months Ended
Jun. 30, 2024

15. RELATED PARTIES In 2018, the Company received $1.5 million from a related party for
assuming an office lease from such party. The liability is amortized through the right-of-use
 Subsequent Events

Subsequent Events [Abstract]

Subsequent Events
 6 Months Ended
Jun. 30, 2024

16. SUBSEQUENT EVENTS Japan Joint Venture On May 18, 2024, the Company entered into a
Joint Venture Agreement (the “Joint Venture Agreement”), by and among SoftBank Group
 Summary of Significant Accounting Policies (Policies)

Accounting Policies [Abstract]

Principles of Consolidation and Basis of Presentation
Reclassification
Emerging Growth Company
Use of Estimates
Net Loss Per Share Attributable to Common Stockholders
Deferred Offering Costs
Recently Issued Accounting Pronouncements Not Yet Adopted
 6 Months Ended
Jun. 30, 2024

Principles of Consolidation and Basis of Presentation The condensed consolidated financial

statements include
Reclassification the accounts
Certain of Tempus
prior year amountsAI, Inc.been
have and reclassified
its wholly owned subsidiaries.
for consistency withAllthe
current
Emergingyear presentation.
Growth Company The Company is an “emerging growth company” as defined in
Section 2(a) of the
Use of Estimates TheSecurities Act, as
preparation ofmodified by thecondensed
the unaudited Jumpstart consolidated
Our Businessfinancial
Startups Act of
statements
Net Loss PerinShare
conformity with GAAP
Attributable requiresStockholders
to Common managementBasic to make
and estimates
diluted netand
loss per share
attributable to common
Deferred Offering Costs stockholders is presented
Deferred offering in conformity
costs consist primarilywith two-class two-class
of accounting, legal, and
other feesIssued
Recently relatedAccounting
to the IPO.Pronouncements
The Company hadNot $ million of deferred
Yet Adopted offering 2023,
In November costs as
theofFASB
issued ASU No. 2023-07, Segment Reporting (Topic 280), which provides enhanced
 Revenue Recognition (Tables)

Revenue Recognition [Abstract]

Summary of Warrant Contract Asset
 6 Months Ended
Jun. 30, 2024

The following summarizes the warrant contract asset presentation as of June 30, 2024 and
December 31, 2023 (in thousands):
 Balance Sheet Components (Tables)

Balance Sheet Related Disclosures [Abstract]

Summary of Property and Equipment
Summary of Depreciation Expenses on Property and Equipment
Summary of Accrued Expenses
 6 Months Ended
Jun. 30, 2024

The following summarizes property and equipment, net as of June 30, 2024 and December
31, 2023 (in thousands):
Depreciation expense on property and equipment is classified as follows in the accompanying
cAccrued
ondensedexpenses as of June 30, 2024 and December 31, 2023, consist of the following (in
thousands):
 Goodwill and Intangibles (Tables)

Goodwill and Intangible Assets Disclosure [Abstract]

Summary of Intangible Assets
 6 Months Ended
Jun. 30, 2024

The following table summarizes intangible assets as of June 30, 2024 and December 31, 2023
(in thousands):
 Redeemable Convertible Preferred Stock (Tables)

Temporary Equity Disclosure [Abstract]

Summary of Redeemable Convertible Preferred Stock Outstanding
 6 Months Ended
Jun. 30, 2024

Redeemable convertible preferred stock outstanding as of December 31, 2023 consisted of

the following (in thousands, except share amounts):
 Stock-based compensation (Tables)

Share-Based Payment Arrangement [Abstract]

Schedule of Stock-based Compensation Expense Recorded in Consolidated Statements of
Operations
Schedule of the activity related to the Company's RSUs
 6 Months Ended
Jun. 30, 2024

Stock-based compensation is classified as follows in the accompanying condensed

Three
The months
table ended
below June 30,restricted
summarizes Six months ended
stock June
unit 30, under the 2015 Plan for the six
activity
months ended June 30, 2024:
 Net Loss Per Share Attributable to Common Stockholders (Tables)

Earnings Per Share [Abstract]

Schedule of Calculation for Basic and Diluted Net Loss Per Share
Schedule of Antidilutive Securities Excluded From the Computation of Earnings Per Share
 6 Months Ended
Jun. 30, 2024

The following table presents the calculation for basic and diluted net loss per share (in
thousands, except
The following share andshares
outstanding per share data): stock equivalents were excluded from the
of common
calculation of diluted net loss per share for each period, as the impact of including them would
 Fair Value Measurements (Tables)

Fair Value Disclosures [Abstract]

Schedule of Portion of Unrealized Gains Relate to Marketable Equity Securities
Schedule of the Assumption Used in the Model Table
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis
Schedule of Fair Value Assets and Liabilty Measured on Unobservable Input Reconciliation
 6 Months Ended
Jun. 30, 2024

The following summarizes the portion of unrealized gains recorded during the three and six
months
The endedtable
following June summarizes
30, 2024 thatthe
relate to marketable
assumptions used securities held
in the model asas
ofof June
June 30,30, 2024 (in
2024:
Expected term tables
The following (in years) 2.50 assets and liabilities that are measured at fair value on a
summarize
recurring basis as of June 30, 2024
The following tables provide and December
a reconciliation 31,
of the 2023 (inand
beginning thousands):
ending balances for the
assets and liabilities measured at fair value using significant unobservable inputs (Level 3) (in
 Description of Business - Additional Information (Detail) - USD ($) $ / shares in Units, $
in Thousands
Nature Of Operations [Line Items]
Allocated share based compensation
Temporary equity shares authorized
Common stock shares converted from one class to another
IPO [Member]
Nature Of Operations [Line Items]
Temporary equity shares authorized
Restricted Stock Units (RSUs) [Member] | IPO [Member]
Nature Of Operations [Line Items]
Shares issued, price per share
Allocated share based compensation
Adjustment related to tax witholding for share based compensation
Restricted stock units vested during the period
Common Class A [Member]
Nature Of Operations [Line Items]
Common stock shares authorized
Common stock shares outstanding
Common Class A [Member] | IPO [Member]
Nature Of Operations [Line Items]
Stock issued during period, shares, new issues
Shares issued, price per share
Proceeds from initial public offering
Stock issuance costs
Common stock shares authorized
Common Class A [Member] | Restricted Stock Units (RSUs) [Member]
Nature Of Operations [Line Items]
Share-based payment arrangement, shares withheld for tax withholding obligation
Restricted stock shares issued during the period net of forfeitures shares
Common Class B [Member]
Nature Of Operations [Line Items]
Common stock shares authorized
Common stock shares outstanding
Common Class B [Member] | IPO [Member]
Nature Of Operations [Line Items]
Common stock shares authorized
Series A To Series G Redeemable Convertible Preferred Stock Other Than Class B [Member]
Nature Of Operations [Line Items]
Temporary equity converted into permanent equity common stock shares
Series B B One And B Two Redeemable Convertible Preferred Stock [Member]
Nature Of Operations [Line Items]
Temporary equity converted into permanent equity common stock shares
Series G Three Redeemable Convertible Preferred Stock [Member] | Investor Agreement With
Series
NatureGOfThree Redeemable
Operations [LinePreferred
Items] Stockholders [Member]
Stock issued during the period shares new issues to the holders of temporary equity
Class A Voting Common Stock [Member]
Nature Of Operations [Line Items]
Stock issued during the period value stock dividend
Common stock dividend shares
Class A Voting Stock [Member]
Nature Of Operations [Line Items]
Conversion of non voting common stock into voting stock shares
Class A Voting Stock [Member] | Excercise Of Warrants [Member]
Nature Of Operations [Line Items]
Stock issued during period, shares, new issues
 3 Months Ended 6 Months Ended
Jun. 17, 2024 Jun. 16, 2024 Dec. 08, 2023 Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024

$ 488,313 $0 $ 488,313

331,110

20,000,000

$ 37
$ 488,300
$ 70,800
4,568,291

1,000,000,000 1,000,000,000
149,274,923 149,274,923

11,100,000
$ 37
$ 382,000
$ 28,700
1,000,000,000

1,911,316
4,563,164

5,500,000 5,500,000
5,043,789 5,043,789 5,043,789

5,500,000

66,309,550

5,374,899
236,719

$ 188,200
5,098,799

5,069,477

109,459
6 Months Ended
Jun. 30, 2023 Dec. 31, 2023 Apr. 30, 2022 Dec. 31, 2021

$0
69,803,765

200,228,024 204,590,500 200,228,024

58,367,961

5,374,899 5,374,899
0
Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $
in Thousands
Accounting Policies [Line Items]
Deferred offering costs
IPO [Member]
Accounting Policies [Line Items]
Adjustment to additional paid in capital stock issuance costs
Deferred offering costs
6 Months Ended
Jun. 30, 2024 Dec. 31, 2023

$0 $ 7,085

$ 12,300
$ 7,100
 Revenue Recognition - Summary of Warrant Contract Asset (Detail) - USD ($) $ in
Thousands
Disclosure In Tabular Form Of Warrant Contract Asset As Per Balance Sheet
Classification [Line Items]
Total warrant contract asset
Prepaid Expenses and Other Current Assets [Member]
Disclosure In Tabular Form Of Warrant Contract Asset As Per Balance Sheet
Classification [Line
Prepaid expenses andItems]
other current assets
Warrant Contract Asset Less Current Portion [Member]
Disclosure In Tabular Form Of Warrant Contract Asset As Per Balance Sheet
Classification [Line
Warrant contract Items]
asset, less current portion
Jun. 30, 2024 Dec. 31, 2023

$ 23,920 $ 26,342

4,843 4,843

$ 19,077 $ 21,499
Revenue Recognition - Additional Information (Detail) - USD ($) $ / shares in Units, $ in
Thousands
Disaggregation of Revenue [Line Items]
Revenue from contract with customers excluding assessed tax
Contract with customer liability amount of revenue recognized that was included in the
opening
Accountsbalance
Receivable [Member]
Disaggregation of Revenue [Line Items]
Contract with customer receivable after allowance for credit loss current
Long-Term Contract with Customer [Member]
Disaggregation of Revenue [Line Items]
Revenue, remaining performance obligation
Commercialization and Reference Laboratory Agreement Member With Personalis Inc
[Member]
Disaggregation of Revenue [Line Items]
Term of agreement
Personalis Inc [Member] | Commercialization and Reference Laboratory Agreement Member
With Personalis Inc
Disaggregation [Member][Line Items]
of Revenue
Aggregate milestone amount payable
Cumulative amount paid
Contract with customer assets net current
Personalis Inc [Member] | Commercialization and Reference Laboratory Agreement
[Member]
Disaggregation of Revenue [Line Items]
Class Of Warrant Share Issued
Personalis Inc [Member] | Commercialization and Reference Laboratory Agreement
[Member] | Priorof
Disaggregation December
Revenue31 2024
[Line [Member]
Items]
Class Of Warrant Excisable At Cash
Class of Warrant or Right, Exercise Price of Warrants or Rights
Personalis Inc [Member] | Commercialization and Reference Laboratory Agreement
[Member] | Priorof
Disaggregation December
Revenue31 2025
[Line [Member]
Items]
Class Of Warrant Excisable At Cash
Class of Warrant or Right, Exercise Price of Warrants or Rights
One Year [Member] | Long-Term Contract with Customer [Member]
Disaggregation of Revenue [Line Items]
Revenue, remaining performance obligation, percentage
Two Year [Member] | Long-Term Contract with Customer [Member]
Disaggregation of Revenue [Line Items]
Revenue, remaining performance obligation, percentage
Three Year [Member] | Long-Term Contract with Customer [Member]
Disaggregation of Revenue [Line Items]
Revenue, remaining performance obligation, percentage
Four Year [Member] | Long-Term Contract with Customer [Member]
Disaggregation of Revenue [Line Items]
Revenue, remaining performance obligation, percentage
Genomics Product [Member]
Disaggregation of Revenue [Line Items]
Revenue from contract with customers excluding assessed tax
Genomics Product [Member] | Self-Pay [Member]
Disaggregation of Revenue [Line Items]
Revenue from contract with customers excluding assessed tax
Clinical Order [Member] | Third-Party Payor [Member]
Disaggregation of Revenue [Line Items]
Revenue from contract with customers excluding assessed tax
Insights Product [Member]
Disaggregation of Revenue [Line Items]
Revenue from contract with customers excluding assessed tax
Trials Product [Member]
Disaggregation of Revenue [Line Items]
Revenue from contract with customers excluding assessed tax
Data And Other [Member]
Disaggregation of Revenue [Line Items]
Revenue from contract with customers excluding assessed tax
 3 Months Ended 6 Months Ended
Nov. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023

$ 165,969 $ 132,417 $ 311,789 $ 248,041

39,500 26,400

9,300 9,300 $ 2,400

197,300 197,300

3 years

$ 12,000
7,000 7,000
$ 1,100 $ 1,100 $ 100

9,218,800 9,218,800

4,609,400 4,609,400
$ 1.5 $ 1.5

4,609,400 4,609,400
$ 2.5 $ 2.5

42% 42%

34% 34%

19% 19%

5% 5%
$ 112,300 91,900 $ 214,900 174,000

10,600 7,500 19,800 17,100

101,700 84,400 195,100 156,900

40,700 29,100 72,000 51,900

10,500 10,600 21,800 20,900

$ 53,600 $ 40,500 $ 96,900 $ 74,100

 Business Combinations - Additional Information (Detail) - USD ($) $ in Thousands

Business Acquisition [Line Items]

Goodwill
Payment to acquire business net of cash acquired
Sengine [Member]
Business Acquisition [Line Items]
Goodwill
Business combination aggregate consideration transferred
Payments to acquire businesses, gross
Business combination consideration in the form of shares held back
Sengine [Member] | Maximum [Member]
Business Acquisition [Line Items]
Net working capital adjustment
Sengine [Member] | Nonvoting Common Stock [Member]
Business Acquisition [Line Items]
Business combination consideration transferred equity interests issued and issuable
Business acquisition equity interests issued or issuable number of shares issued
Stock issued during the period shares towards working capital adjustment
Mpirik [Member]
Business Acquisition [Line Items]
Goodwill
Business combination aggregate consideration transferred
Business combination consideration transferred equity interests issued and issuable
Business combination consideration in the form of shares held back
Net working capital adjustment
Business combination aggregate cash consideration payable including the amount witheld
Business combination contingent consideration payable in cash at fair value
Business combination cash consideration held back
Business combination contingent consideration liability based on revenue milestone
Estimated minimum revenue to be attained by the acquiree
Business combination contingent consideration acquisition date fair value
Mpirik [Member] | Restricted Stock Units (RSUs) [Member]
Business Acquisition [Line Items]
Stock issued during the period restricted stock award netof forfeitures
Mpirik [Member] | Other Current Liabilities [Member]
Business Acquisition [Line Items]
Business combination contingent consideration acquisition date fair value
Mpirik [Member] | Nonvoting Common Stock [Member]
Business Acquisition [Line Items]
Stock issued during the period shares in respect of consideration held back
Arterys [Member]
Business Acquisition [Line Items]
Goodwill
Business combination consideration transferred equity interests issued and issuable
Cash consideration
Business combination fair value of consideration net of cash acquired
Cash acquired in a business combination
Payment to acquire business net of cash acquired
Payment of net working capital adjustment
 1 Months Ended 6 Months Ended
Oct. 03, 2023 Mar. 08, 2023 Oct. 03, 2022 Feb. 29, 2024 Jun. 30, 2024 Jun. 30, 2023

$ 73,345
$0 $ 2,869

$ 9,600
9,900
2,800
1,400

100

$ 6,300
35,000
429

$ 10,600
9,700
4,600
300
300
4,700
400
800
1,000
$ 1,500

17,450

$ 400

8,724
$ 11,100
4,900
3,000
8,300
300
3,000
$ 1,000
Jan. 01, 2024 Dec. 31, 2023

$ 73,354

$0
 Balance Sheet Components - Summary of Property and Equipment (Detail) - USD ($) $
in Thousands
Balance Sheet Related Disclosures [Abstract]
Equipment
Leasehold improvements
Furniture and fixtures
Total property and equipment, gross
Less: accumulated depreciation
Property and equipment, net
Jun. 30, 2024 Dec. 31, 2023

$ 101,631 $ 91,656
44,000 42,433
6,633 6,633
152,264 140,722
(91,725) (79,041)
$ 60,539 $ 61,681
 Balance Sheet Components - Summary of Depreciation Expenses on Property and
Equipment (Detail) - USD ($) $ in Thousands
Property Plant and Equipment Income Statement Disclosures [Abstract]
Cost of revenue, genomics
Selling, general and administrative costs
Total depreciation
 3 Months Ended 6 Months Ended
Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023

$ 3,293 $ 3,222 $ 6,674 $ 6,363

3,122 1,972 6,010 3,891
$ 6,415 $ 5,194 $ 12,684 $ 10,254
 Balance Sheet Components - Summary of Accrued Expenses (Detail) - USD ($) $ in
Thousands
Balance Sheet Related Disclosures [Abstract]
Accrued compensation and employee benefits
Accrued expenses
Accrued cloud storage costs
Interest payable
Total accrued expenses
Jun. 30, 2024 Dec. 31, 2023

$ 18,532 $ 21,950
44,053 37,783
13,723 13,921
8,877 8,863
$ 85,185 $ 82,517
 Goodwill and Intangibles - Summary of Intangible Assets (Detail) - USD ($) $ in
Thousands
Finite And Indefinitely Lived Intangible Assets [Line Items]
Gross Amount
Accumulated Amortization
Net
Website domain [Member]
Finite And Indefinitely Lived Intangible Assets [Line Items]
Indefinite lived intangible sssets
Customer relationships [Member]
Finite And Indefinitely Lived Intangible Assets [Line Items]
Gross Amount
Accumulated Amortization
Net
Licensed data [Member]
Finite And Indefinitely Lived Intangible Assets [Line Items]
Gross Amount
Accumulated Amortization
Net
Trade names [Member]
Finite And Indefinitely Lived Intangible Assets [Line Items]
Gross Amount
Accumulated Amortization
Net
Jun. 30, 2024 Dec. 31, 2023

$ 47,891 $ 47,890
31,638 25,974
16,252 21,916

19 19

20,550 20,550
13,913 12,219
6,637 8,331

19,321 19,321
14,868 11,469
4,453 7,852

8,000 8,000
2,857 2,286
$ 5,143 $ 5,714
 Goodwill and Intangibles - Additional Information (Detail) - USD ($)

Finite And Indefinitely Lived Intangible Assets [Line Items]

Goodwill, acquired during period
Goodwill, impairment loss
Impairment of intangible assets, finite-lived
Operating Cost and Expenses [Member]
Finite And Indefinitely Lived Intangible Assets [Line Items]
Amortization of intangible assets
Mpirik [Member]
Finite And Indefinitely Lived Intangible Assets [Line Items]
Goodwill, acquired during period
Maximum [Member]
Finite And Indefinitely Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life
Minimum [Member]
Finite And Indefinitely Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life
Weighted Average [Member]
Finite And Indefinitely Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life
Licensed Data [Member] | DeIdendified Data Through Additional Agreement [Member]
Finite And Indefinitely Lived Intangible Assets [Line Items]
Additions to finite lived intangible assets
Licensed Data [Member] | Research And Development Process [Member]
Finite And Indefinitely Lived Intangible Assets [Line Items]
Impairment of intangible assets, finite-lived
Gain loss due to saving in future payments due on intangible assets
Reduction in gross value of intangible assets
Reduction in accumulated amortization of finite lived intangible assets
 3 Months Ended 6 Months Ended
Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023

$0 $0 $0
0 0 0 $0
0 0 0 0

$ 2,800,000 3,100,000 $ 5,700,000 6,000,000

10,600,000

7 years 7 years

3 years 3 years

6 years 6 years

$0 3,800,000

7,400,000
$ 7,900,000
$ 40,100,000
$ 32,700,000
Stockholders' Equity - Additional Information (Detail) $ / shares in Units, $ in Millions

Class of Stock [Line Items]

Preferred stock shares authorized
Treasury Stock, Common [Member]
Class of Stock [Line Items]
Stock repurchased during the period shares
Allen and Company LLC [Member] | Warrants Convertible Into Class A Common Stock
[Member]
Class of Stock [Line Items]
Class of warrants or rights number of securities covered by warrants or rights
Class of warrants or rights exercise price | $ / shares
Common Class A [Member]
Class of Stock [Line Items]
Common stock shares authorized
Common Class A [Member] | Exercise of Warrants [Member]
Class of Stock [Line Items]
Stock issued during period shares new issues
Common Class A [Member] | Master Services Agreement With Astra Zeneca As Amended
[Member]
Class of Stock [Line Items]
Class of warrants value of shares covered by warrants or rights | $
Class of warrants or rights number of securities covered by warrants or rights
Class of warrants or rights exercise price | $ / shares
Commitment of the counterparty | $
Commitment of the counterparty if warrants are exercised | $
Common Class B [Member]
Class of Stock [Line Items]
Common stock shares authorized
Stockholders equity stock split
Duration before which shares may be converted from one class to another
Share holding below which trigger is caused for conversion of stock from one class to another
Common Class B [Member] | Maximum [Member]
Class of Stock [Line Items]
Number of days for determining conversion of stock from class to another
Number of days for determining ownership of the founder below which conversion of stock
from
Commonone Class
class to another is |triggered
B [Member] Minimum [Member]
Class of Stock [Line Items]
Number of days for determining conversion of stock from class to another
Number of days for determining ownership of the founder below which conversion of stock
from one class
Non-voting to another
Common Stockis[Member]
triggered
Class of Stock [Line Items]
Common stock shares authorized
Non-voting Common Stock [Member] | Treasury Stock, Common [Member]
Class of Stock [Line Items]
Stock repurchased during the period shares
 1 Months Ended 6 Months Ended
Dec. 08, 2023 $ / shares shares Jan. 31, 2023 shares Jun. 30, 2024 USD ($) shares

20,000,000

150,000
$ 10

1,000,000,000

109,459

$ 220
$ 320

5,500,000
1
20 years
10,000,000

150 days
150 days

90 days
90 days

0
145,466
Months Ended
Jun. 30, 2023 shares Dec. 31, 2023 shares Apr. 30, 2022 shares

(145,466)

200,228,024 204,590,500

5,374,899

66,946,627
Dec. 31, 2021 USD ($) $ / shares shares

200,228,024

$ 100
2,702,703
$ 37

5,374,899

63,946,627
 Redeemable Convertible Preferred Stock - Summary of Redeemable Convertible
Preferred Stock Outstanding (Detail) - USD ($) $ in Thousands
Temporary Equity [Line Items]
Shares Authorized
Shares Outstanding
Liquidation Amount
Carrying Value
Series A [Member]
Temporary Equity [Line Items]
Shares Authorized
Shares Outstanding
Liquidation Amount
Carrying Value
Series B [Member]
Temporary Equity [Line Items]
Shares Authorized
Shares Outstanding
Liquidation Amount
Carrying Value
Series B-1 [Member]
Temporary Equity [Line Items]
Shares Authorized
Shares Outstanding
Liquidation Amount
Carrying Value
Series B-2 [Member]
Temporary Equity [Line Items]
Shares Authorized
Shares Outstanding
Liquidation Amount
Carrying Value
Series C [Member]
Temporary Equity [Line Items]
Shares Authorized
Shares Outstanding
Liquidation Amount
Carrying Value
Series D [Member]
Temporary Equity [Line Items]
Shares Authorized
Shares Outstanding
Liquidation Amount
Carrying Value
Series E [Member]
Temporary Equity [Line Items]
Shares Authorized
Shares Outstanding
Liquidation Amount
Carrying Value
Series F [Member]
Temporary Equity [Line Items]
Shares Authorized
Shares Outstanding
Liquidation Amount
Carrying Value
Series G [Member]
Temporary Equity [Line Items]
Shares Authorized
Shares Outstanding
Liquidation Amount
Carrying Value
Series G-2 [Member]
Temporary Equity [Line Items]
Shares Authorized
Shares Outstanding
Liquidation Amount
Carrying Value
Series G-3 [Member]
Temporary Equity [Line Items]
Shares Authorized
Shares Outstanding
Liquidation Amount
Carrying Value
Series G-4 [Member]
Temporary Equity [Line Items]
Shares Authorized
Shares Outstanding
Liquidation Amount
Carrying Value
Jun. 30, 2024 Dec. 31, 2023

69,803,765
63,525,953
$ 1,130,429
$0 $ 1,105,543

10,000,000
10,000,000
$ 10,500
$ 10,000

5,374,899
5,374,899
$ 10,500
$ 10,000

2,500,000
2,500,000
$ 10,500
$ 10,000

4,191,173
4,191,173
$ 31,500
$ 30,000

9,779,403
9,779,403
$ 86,757
$ 70,000

8,534,330
8,534,330
$ 105,107
$ 104,145
6,630,905
6,630,905
$ 151,621
$ 151,621

8,077,674
8,077,674
$ 261,722
$ 261,722

2,537,290
2,537,290
$ 119,928
$ 119,928

3,453,139
3,453,139
$ 197,889
$ 197,889

4,362,476
1,661,895
$ 98,891
$ 95,238

4,362,476
785,245
$ 45,514
$ 45,000
Redeemable Convertible Preferred Stock - Additional Information (Detail) - USD ($) $ /
shares in Units, $ in Thousands
Temporary Equity [Line Items]
Proceeds from redeemable convertible preferred stock
Series G-3 Redeemable Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Temporary equity stock issued during the period shares payment of dividend in kind
Series G-4 Redeemable Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Temporary equity stock issued during the period shares payment of dividend in kind
Series G-5 Redeemable Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Temporary equity stock issued during the period shares new issues
Proceeds from redeemable convertible preferred stock
Temporary equity par or stated value per share
Temporary equity special payment as a percentage of original issue price
Aggregate trading period for determining special price payable to the holders of temporary
equity
Common stock average price as percentage of issue price maximum
Series G-5 Redeemable Convertible Preferred Stock [Member] | Accrued Liabilities [Member]
Temporary Equity [Line Items]
Special price payable current
Common Class A [Member]
Temporary Equity [Line Items]
Common stock shares outstanding
Temporary equity converted into permanent equity shares
Common Class B [Member]
Temporary Equity [Line Items]
Common stock shares outstanding
 1 Months Ended 3 Months Ended 6 Months Ended
Apr. 30, 2024 Jan. 31, 2024 Oct. 31, 2023 Jan. 31, 2023 Jun. 30, 2024 Jun. 30, 2024

$ 199,750

66,465 47,781

10,666

3,489,981 785,245
$ 200,000 $ 45,000
$ 0.0001 $ 0.0001
5%
10 days
110%

$ 2,300 $ 2,300

149,274,923 149,274,923
71,976,178

5,043,789 5,043,789
6 Months Ended
Jun. 30, 2023 Jun. 17, 2024 Dec. 31, 2023

$0

58,367,961

5,043,789 0
 Stock-based compensation - Additional Information (Detail) - USD ($) $ in Millions

2015 Stock Option Plan [Member]

Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation by share based award number of shares authorized for issue
2015 Stock Option Plan [Member] | Restricted Stock Units (RSUs) [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation by share based award equity instruments other than options
granted during
Share based the period by share based award incremental compensation costs
compensation
Share based compensation by share based award vesting period
Share based compensation by share based award unrecognized compensation equity
instruments other than options
Share based compensation by share based award unrecognized compensation remaining
periodStock
2015 for recognition
Option Plan [Member] | Restricted Stock Units (RSUs) [Member] | Share-Based
Payment Arrangement,
Share-Based Payment Tranche One [Member]
Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation by share based award vesting percentage
2024 Equity Incentive Plan [Member] | Incentive Stock Options [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation by share based award number of shares available for issue
2024 Equity Incentive Plan [Member] | Common Class A [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation by share based award number of shares available for issue
Share based compensation by share based payment award expiration date
2024 Equity Incentive Plan [Member] | Class A And Class B Common Stock [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation by share based award number of additional shares available for
issue as a percentage of outstanding common stock
 1 Months Ended 3 Months Ended 6 Months Ended
Jul. 31, 2024 Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023

1,647,906 1,933,606
$ 47.5 $ 35.3 $ 47.5 $ 35.3
4 years
$ 125.3 $ 125.3
1 year 4 months 24 days

20%

22,290,000 22,290,000

7,430,000 7,430,000
Jan. 01, 2034

5% 5%
Dec. 31, 2023

28,115,750
 Stock-based compensation - Schedule of the activity related to the Company's RSUs
(Detail) - Two Thousand and Fifteen Plan [Member] - Restricted Stock Units (RSUs)
[Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Unvested at December 31, 2023 | shares
Granted | shares
Vested and settled | shares
Vested and not yet settled | shares
Forfeited | shares
Expired | shares
Unvested at June 30, 2024 | shares
Unvested at December 31, 2023 | $ / shares
Granted | $ / shares
Vested and settled | $ / shares
Vested and not yet settled | $ / shares
Forfeited | $ / shares
Expired | $ / shares
Unvested at June 30, 2024 | $ / shares
 6 Months Ended
Jun. 30, 2024 $ / shares shares

20,788,500
1,933,606
(4,563,164)
(10,870,652)
(457,785)
(147,376)
6,683,129
$ 26.47
37.59
11.93
24.46
25.58
0.28
$ 36.77
 Stock-based compensation - Schedule of Stock-based Compensation Expense Recorded
in Consolidated Statements of Operations (Detail) - USD ($) $ in Thousands
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation, expense
Cost of Revenue Genomics [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation, expense
Cost of Revenue Data and Services [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation, expense
Technology Research and Development [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation, expense
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation, expense
Selling, General and Administrative Expenses [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation, expense
 3 Months Ended 6 Months Ended
Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023

$ 488,313 $0 $ 488,313 $0

11,327 0 11,327 0

7,229 0 7,229 0

50,434 0 50,434 0

42,233 0 42,233 0

$ 377,090 $0 $ 377,090 $0
 Debt - Additional Information (Detail)

Debt Instrument [Line Items]

Proceeds from long term debt net of issuance costs and discount
Payment of interest on debt
Fed Funds Effective Rate Overnight Index Swap Rate [Member]
Debt Instrument [Line Items]
Debt instrument variable interest rate spread percentage based on which the borrowing type
can be converted
Secured Overnightinto base rate
Financing Rate (SOFR) Overnight Index Swap Rate [Member]
Debt Instrument [Line Items]
Debt instrument variable interest rate spread percentage based on which the borrowing type
can
TermbeLoan
converted into base
Agreement Withrate
Ares Capital Corporation [Member]
Debt Instrument [Line Items]
Debt instrument face value
Long term debt unamortized discount gross
Long term debt unamortized debt issuance costs gross
Long term debt variable interest rate percentage
Term Loan Amendment Agreement One With Ares Capital Corporation [Member]
Debt Instrument [Line Items]
Debt instrument face value
Long term debt unamortized discount gross
Increase in interest rate percentage on term loan facility
Long term debt variable interest rate percentage
Term Loan Agreement Including Amendment Agreement One And Two With Ares Capital
Corporation [Member]
Debt Instrument [Line Items]
Long term debt unamortized discount gross
Long term debt unamortized debt issuance costs gross
Minimum liquidity required to be maintained value
Long term debt unamortized debt issuance costs net
Payment of interest on debt
Long term debt variable interest rate percentage
Interest expenses
Term Loan Agreement Including Amendment Agreement One And Two With Ares Capital
Corporation [Member]
Debt Instrument [Line| Items]
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate
Debt instrument variable interest rate spread percentage
Debt instument paid in kind interest percentage
Term Loan Agreement Including Amendment Agreement One And Two With Ares Capital
Corporation [Member]
Debt Instrument [Line| Items]
Base Rate [Member]
Debt instrument variable interest rate spread percentage
Debt instument paid in kind interest percentage
Term Loan Agreement Including Amendment Agreement One And Two With Ares Capital
Corporation [Member]
Debt Instrument [Line| Items]
Base Rate One [Member]
Debt instrument variable interest rate spread percentage
Term Loan Agreement Including Amendment Agreement One And Two With Ares Capital
Corporation [Member]
Debt Instrument [Line| Items]
Term Secured Overnight Financing Rate One [Member]
Debt instrument variable interest rate spread percentage
Term Loan Amendment Agreement Two With Ares Capital Corporation [Member]
Debt Instrument [Line Items]
Debt instrument face value
Long term debt unamortized discount gross
Proceeds from long term debt net of issuance costs and discount
Long term debt maturity date
Term Loan Amendment Agreement Two With Ares Capital Corporation [Member] | SOFR One
[Member]
Debt Instrument [Line Items]
Debt instrument variable interest rate spread percentage based on which the borrowing type
can be converted
Convertible Notesinto base [Member]
Payable rate
Debt Instrument [Line Items]
Debt instrument face value
Fair value of liabilities measured using significant unobservable input issues during the
period
Amended And Restated Convertible Promissory Note [Member]
Debt Instrument [Line Items]
Debt instrument face value
Long term debt maturity date
Interest expenses
Principal amount to be payable after prepayment value
Debt instrument convertible threshold period of consecutive trading days | Day
Forecast [Member] | Term Loan Agreement Including Amendment Agreement One And Two
With
Debt Ares Capital Corporation
Instrument [Line Items][Member] | Twelve Months Ended Thirty First Of December
Revenue
Forecast [Member] | Term Loan Agreement Including Amendment Agreement One And Two
With
Debt Ares Capital Corporation
Instrument [Line Items][Member] | Twelve Months Ended Thirty First Of December
Revenue
Series G Two Redeemable Convertible Preferred Stock [Member] | Convertible Notes Payable
[Member]
Debt Instrument [Line Items]
Temporary equity stock issued during period value new issues
Redeemable preferred stock discount rate percentage
Oct. 11, 2023 USD ($) Nov. 19, 2020 USD ($) Jun. 22, 2020 USD ($) Day

0.50%

1%

$ 6,500,000
2,600,000
$ 25,000,000

5%
3.25%

4%
3.25%

6.25%
 7.25%

$ 35,000,000
900,000
$ 34,100,000
Sep. 22, 2027

2%

$ 330,000,000
330,000,000

$ 250,000,000
Mar. 22, 2026

$ 150,000,000
20

$ 80,000,000
10%
 3 Months Ended 6 Months Ended
Jun. 30, 2024 USD ($) Jun. 30, 2023 USD ($) Jun. 30, 2024 USD ($) Jun. 30, 2023 USD ($)

$0 $ 48,750,000
13,921,000 5,691,000

$ 175,000,000 $ 175,000,000

9.89% 9.89%

$ 50,000,000 $ 50,000,000

10.07% 10.07%

$ 4,500,000 4,500,000

$ 1,600,000 1,600,000
$ 13,900,000
10.30% 10.30%
$ 9,200,000 $ 6,900,000 $ 18,300,000 $ 12,000,000
$ 3,700,000 $ 3,800,000 $ 7,300,000 $ 7,600,000
 12 Months Ended
Dec. 31, 2025 USD ($) Dec. 31, 2024 USD ($) Dec. 31, 2023 USD ($) Apr. 25, 2023 USD ($)

$ 50,000,000
$ 1,300,000
0.25%

$ 5,100,000

$ 1,900,000
 $ 459,100,000

$ 594,100,000
Sep. 22, 2022 USD ($)

$ 175,000,000
4,400,000
$ 2,600,000
 Net Loss Per Share Attributable to Common Stockholders - Schedule of Calculation for
Basic and Diluted Net Loss Per Share (Detail) - USD ($) $ / shares in Units, $ in
Thousands
Numerator:
Net Income (Loss)
Dividends on Series A, B, B-1, B-2, C, D, E, F, G, G-3, and G-4 preferred shares
Cumulative Undeclared Dividends on Series C preferred shares
Net loss attributable to common stockholders, Basic
Net loss attributable to common stockholders, Diluted
Denominator:
Weighted-average common shares outstanding, basic
Weighted-average common shares outstanding, diluted
Net loss per share attributable to common stockholders, basic
Net loss per share attributable to common stockholders, diluted
 3 Months Ended 6 Months Ended
Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023

$ (552,212) $ (55,832) $ (616,955) $ (110,209)

(11,540) (10,897) (39,347) (21,566)
(668) (745) (1,174) (1,466)
(564,420) (67,474) (657,476) (133,241)
$ (564,420) $ (67,474) $ (657,476) $ (133,241)

82,325 63,286 72,930 63,257

82,325 63,286 72,930 63,257
$ (6.86) $ (1.07) $ (9.02) $ (2.11)
$ (6.86) $ (1.07) $ (9.02) $ (2.11)
 Net Loss Per Share Attributable to Common Stockholders - Schedule of Antidilutive
Securities Excluded From the Computation of Earnings Per Share (Detail) - shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares
Stock options outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares
AstraZeneca warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares
Mpirik holdback liability [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares
SEngine holdback liability [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares
Sengine contingent consideration [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares
Unvested RSUs [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares
 6 Months Ended
Jun. 30, 2024 Jun. 30, 2023

9,671,839 1,963,715

210,000 210,000

2,702,703 1,744,991

8,724

41,007

35,000

6,683,129
 Net Loss Per Share Attributable to Common Stockholders - Additional Information
(Detail) $ in Millions
Class A Voting Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Class of warrants or rights issued during the period value
 1 Months Ended
Oct. 31, 2022 USD ($)

$ 100
 3 Months Ended
Income Taxes - Additional Information (Detail) - USD ($) $ in Millions
Jun. 30, 2024
Maximum [Member]
Income Tax [Line Items]
Income tax expense (benefit) $ 0.2
3 Months Ended 6 Months Ended
Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023

$ 0.2 $ 0.2 $ 0.2

 Fair Value Measurements - Additional Information (Detail) - USD ($) $ / shares in
Thousands, $ in Thousands
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent consideration classified as equity, fair value disclosure
Proceeds from sale of marketable equity securities
Investment In Recursion Pharmaceuticals Class A Common Stock [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investment in equity securities at fair value sold number of shares
Weighted average price per share of investment sold
Proceeds from sale of marketable equity securities
Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent consideration classified as equity, fair value disclosure
Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent consideration classified as equity, fair value disclosure
Company recognised expenses due change fair value of warrant liability
Company recognized gain due change fair value of warrant liability
Warrant [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Warrant issued
Contingent Consideration [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent consideration cash payment
Contingent upon revenue target
Contingent consideration classified as equity, fair value disclosure
Contingent Consideration [Member] | Common Stock [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent consideration arrangement of non voting common stock
Contingent Consideration [Member] | Common Stock [Member] | Fair Value, Inputs, Level 1
[Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent consideration arrangement of non voting common stock
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023

$ 940 $ 940 $ 775

$ 23,098 $0

1,725,902
$ 13,380
$ 23,100

940 940 0

0 0 775
1,700 $ 700
900 $ 5,700

100,000

1,000
$ 1,500
$ 800 $ 800

35,000

35,000
 Fair Value Measurements - Schedule of Portion of Unrealized Gains Relate to
Marketable Equity Securities (Detail) - USD ($) $ in Thousands
Gain (Loss) on Securities [Line Items]
Net (loss) gain during the period on marketable equity securities
Less: Net gain recognized during the period on marketable equity securities sold during the
period
Unrealized gain recognized during the period on marketable equity securities still held at the
reporting date
3 Months Ended 6 Months Ended
Jun. 30, 2024 Jun. 30, 2024 Jun. 30, 2023

$ (3,705) $ 2,541 $0
0 (6,081)
$ (3,705) $ (3,540)
 Fair Value Measurements - Schedule of the Assumption Used in the Model Table
(Detail)
Expected term (in years) [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input
Risk-free interest rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input
Expected volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input
Expected dividend yield [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input
Jun. 30, 2024 yr

2.5

4.51

55

0
 Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on
Recurring Basis (Detail) - USD ($) $ in Thousands
Assets, Fair Value Disclosure [Abstract]
Marketable equity securities
Warrant asset
Liabilities, Fair Value Disclosure [Abstract]
Warrant liability
Contingent consideration
Fair Value, Inputs, Level 1 [Member]
Assets, Fair Value Disclosure [Abstract]
Marketable equity securities
Warrant asset
Liabilities, Fair Value Disclosure [Abstract]
Warrant liability
Contingent consideration
Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value Disclosure [Abstract]
Marketable equity securities
Warrant asset
Liabilities, Fair Value Disclosure [Abstract]
Warrant liability
Contingent consideration
Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value Disclosure [Abstract]
Marketable equity securities
Warrant asset
Liabilities, Fair Value Disclosure [Abstract]
Warrant liability
Contingent consideration
Jun. 30, 2024 Dec. 31, 2023

$ 11,255 $ 31,807
2,300 10,000

33,600 34,500
940 775

11,255 31,807
0 0

0 0
940 0

0 0
2,300 10,000

0 0
0 0

0 0
0 0

33,600 34,500
$0 $ 775
 Fair Value Measurements - Schedule of Fair Value Assets and Liabilty Measured on
Unobservable Input Reconciliation (Detail) - Fair Value, Inputs, Level 3 [Member] - USD
($) $ in Thousands
Warrant Liability [Member]
Fair Value Assets And Liability Measured On Unobservable Input Reconciliation [Line
Items]
Beginning balances for the assets and liabilities measured at fair value
Change in fair value of warrant liability
Contingent consideration from Mpirik acquisition
Change in fair value of contingent consideration
Transfer out of Level 3
Ending balances for the assets and liabilities measured at fair value
Contingent Consideration [Member]
Fair Value Assets And Liability Measured On Unobservable Input Reconciliation [Line
Items]
Beginning balances for the assets and liabilities measured at fair value
Change in fair value of warrant liability
Contingent consideration from Mpirik acquisition
Change in fair value of contingent consideration
Transfer out of Level 3
Ending balances for the assets and liabilities measured at fair value
 6 Months Ended
Jun. 30, 2024 Jun. 30, 2023

$ 34,500 $ 42,500
(900) (5,700)
0
0
0
33,600 36,800

775 0
0 0
400
194
(969)
$0 $ 400
 Related Parties - Additional Information (Detail) - USD ($) $ / shares in Units, $ in
Thousands
Related Party [Member]
Related Party Transaction [Line Items]
Aamount receive from related party
Related party transaction due from to related party
Pathos [Member]
Related Party Transaction [Line Items]
Due to related parties
Pathos [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Related party transaction due from to related party
Revenue from the arrangement
Revenue from the additional arrangement
Pathos [Member] | Subscription Arrangement [Member]
Related Party Transaction [Line Items]
Subscription fee payable for year wise
Revenue from subscription fee
Warrant [Member] | Pathos [Member]
Related Party Transaction [Line Items]
Received warrant to purchase share
Percentage of current outstanding equity
Common stock par or stated value per share
Warrant optional exercise election window term
 3 Months Ended 6 Months Ended
Aug. 19, 2021 Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023

$ 700 $ 700

0 0

100 100
300 $ 300 300 $ 300
100 100 100 100

$ 400
$ 100 $ 200 $ 100 $ 200

23,456,790
19%
$ 0.0125
10 days of the 20 year term
12 Months Ended
Dec. 31, 2018 Dec. 31, 2023

$ 1,500
$ 700

$ 100
 Subsequent Events - Additional Information (Detail) - Jul. 18, 2024 - Subsequent Event
[Member] $ in Millions
Investment In Japan Joint Venture Pursuant to Joint Venture Agreement [Member]
Subsequent Event [Line Items]
Equity method investment ownership percentage
Co-venturer [Member] | Investment In Japan Joint Venture Pursuant to Joint Venture
Agreement
Subsequent[Member]
Event [Line Items]
Equity method investment ownership percentage
Corporate Joint Venture Between the Company and the Soft Bank Group Japan [Member]
Subsequent Event [Line Items]
Common stock value
Corporate Joint Venture Between the Company and the Soft Bank Group Japan [Member] |
Data License Event
Subsequent Agreement
[Line[Member]
Items]
Proceeds from license fees
Corporate Joint Venture Between the Company and the Soft Bank Group Japan [Member] |
Intellectual
SubsequentProperty License
Event [Line Agreement [Member]
Items]
Proceeds from license fees
USD ($) JPY (¥) JPY (¥)

50% 50%

50% 50%

$ 191.1 ###

47.8 ###

$ 47.8 ###